STOCK TITAN

Exponent (NASDAQ: EXPO) grows Q1 2026 revenue 14% and expands buybacks

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Exponent, Inc. reported first-quarter 2026 revenue of $166.3 million, up 14.3% from $145.5 million a year earlier, driven by strong Engineering and Other Scientific work and AI-related user research and utility risk management projects. Revenues before reimbursements rose 10% to $151.8 million.

Net income increased 11% to $29.6 million, with diluted EPS rising to $0.59 from $0.52. EBITDA reached $43.1 million, and EBITDA as a percentage of revenues before reimbursements improved to 28.4%. The company returned capital through a $0.31 per-share dividend, Q1 share repurchases of about $78.8 million, and a new $50 million buyback authorization.

Positive

  • None.

Negative

  • None.
Revenue $166.3 million Three months ended April 3, 2026
Net income $29.6 million Three months ended April 3, 2026
Diluted EPS $0.59 per share Three months ended April 3, 2026
EBITDA $43.1 million Three months ended April 3, 2026
EBITDA margin 28.4% EBITDA as % of revenues before reimbursements, Q1 2026
Cash and cash equivalents $118.6 million As of April 3, 2026
Share repurchases 1.156 million shares, $78.8 million Three months ended April 3, 2026
Quarterly dividend $0.31 per share Declared April 30, 2026, payable June 18, 2026
EBITDA financial
"We define EBITDA as net income before income taxes, net interest income, depreciation and amortization."
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.
EBITDAS financial
"We define EBITDAS as EBITDA before stock-based compensation."
EBITDAs are measures of a company’s operating profit calculated before subtracting interest, taxes, depreciation and amortization. Think of it as the cash-like earnings from running the business—revenue minus routine operating costs—before loan payments and accounting adjustments; investors use it to compare underlying performance across companies and industries. It matters because it highlights core cash-generating ability, but it does not replace full profit or cash-flow analysis.
deferred compensation plan financial
"The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees."
A deferred compensation plan is an arrangement where an employer agrees to pay part of an employee’s pay or bonus at a later date instead of immediately, often to reduce current tax bills or to tie rewards to long-term performance. For investors it matters because these promises create future cash obligations and influence executive incentives and retention; they can affect a company’s reported liabilities, cash flow planning and the risk profile if the business faces financial trouble.
restricted stock unit financial
"Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
utilization financial
"Our utilization increased 1% to 76% as compared to 75% during the same period last year."
Utilization measures how much a resource, service or capacity is actually used compared with how much is available, like tracking how often a car in a fleet is on the road versus sitting idle. For investors it signals demand, efficiency and future revenue potential—high utilization can mean strong sales and better returns but also risk of capacity strain or higher costs, while low utilization can indicate weak demand or excess capacity.
time and materials contracts financial
"Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements."
--01-010000851520Q1false59.559.559.559.559.559.5http://fasb.org/srt/2025#ChiefExecutiveOfficerMemberhttp://fasb.org/srt/2025#ChiefExecutiveOfficerMemberOne year0000851520us-gaap:CommonStockMember2025-04-040000851520expo:OfficeLaboratoryAndStorageSpaceMembersrt:MinimumMember2026-04-030000851520us-gaap:AdditionalPaidInCapitalMember2026-01-020000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-01-042025-04-040000851520expo:OfficeLaboratoryAndStorageSpaceMember2026-04-030000851520us-gaap:RetainedEarningsMember2025-04-040000851520us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2026-01-020000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-020000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2026-01-032026-04-030000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2025-01-042025-04-040000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2026-01-032026-04-030000851520expo:OfficeLaboratoryAndStorageSpaceMembersrt:MaximumMember2026-04-030000851520us-gaap:FairValueInputsLevel3Member2026-04-030000851520us-gaap:EquitySecuritiesMember2026-01-020000851520us-gaap:FairValueInputsLevel3Member2026-01-020000851520expo:UnvestedRestrictedStockAwardsMember2026-01-032026-04-030000851520us-gaap:CashAndCashEquivalentsMember2026-04-030000851520us-gaap:TreasuryStockCommonMember2026-04-030000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2026-01-032026-04-030000851520us-gaap:UnbilledRevenuesMember2026-01-020000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMemberus-gaap:FixedPriceContractMember2026-01-032026-04-030000851520us-gaap:OtherOperatingIncomeExpenseMember2025-01-042025-04-040000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-04-040000851520us-gaap:EquitySecuritiesMember2026-04-030000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2025-01-042025-04-040000851520us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2026-04-030000851520us-gaap:CorporateNonSegmentMember2026-01-032026-04-030000851520us-gaap:OperatingSegmentsMember2026-01-032026-04-030000851520us-gaap:FairValueInputsLevel2Member2026-04-030000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-032026-04-030000851520us-gaap:OtherIncomeMember2026-01-032026-04-030000851520us-gaap:MoneyMarketFundsMember2026-04-030000851520us-gaap:OperatingSegmentsMember2025-01-042025-04-040000851520us-gaap:EmployeeStockOptionMember2025-01-042025-04-040000851520us-gaap:EmployeeStockOptionMember2026-01-032026-04-030000851520us-gaap:AdditionalPaidInCapitalMember2025-01-042025-04-040000851520us-gaap:TreasuryStockCommonMember2025-04-0400008515202025-04-040000851520us-gaap:FairValueInputsLevel2Member2026-01-020000851520us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2026-04-030000851520us-gaap:BilledRevenuesMember2026-04-0300008515202026-01-020000851520us-gaap:CashMember2026-04-030000851520us-gaap:CommonStockMember2026-04-030000851520expo:O2026Q2DividendsMemberus-gaap:SubsequentEventMember2026-04-300000851520us-gaap:OtherOperatingIncomeExpenseMember2026-01-032026-04-030000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-030000851520us-gaap:OtherIncomeMember2025-01-042025-04-040000851520us-gaap:AdditionalPaidInCapitalMember2026-01-032026-04-030000851520us-gaap:FixedIncomeSecuritiesMember2026-01-020000851520us-gaap:MoneyMarketFundsMember2026-01-020000851520us-gaap:CashEquivalentsMember2026-01-0200008515202026-05-010000851520us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2026-01-020000851520us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2026-01-020000851520us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-01-020000851520us-gaap:TreasuryStockCommonMember2026-01-020000851520us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2026-01-020000851520us-gaap:CorporateNonSegmentMember2025-01-042025-04-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-0400008515202026-04-030000851520expo:UnvestedRestrictedStockAwardsMembersrt:MinimumMember2026-01-032026-04-030000851520us-gaap:BilledRevenuesMember2026-01-020000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-042025-04-040000851520expo:PhoenixArizonaMember2026-01-032026-04-0300008515202025-01-030000851520expo:VestedRestrictedStockAwardsMember2025-01-042025-04-040000851520us-gaap:RetainedEarningsMember2026-04-030000851520us-gaap:TreasuryStockCommonMember2026-01-032026-04-030000851520us-gaap:RetainedEarningsMember2026-01-020000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-030000851520us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2026-04-030000851520expo:UnvestedRestrictedStockAwardsMember2025-01-042025-04-040000851520us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2026-04-030000851520us-gaap:FairValueInputsLevel1Member2026-01-020000851520us-gaap:CashMember2026-01-020000851520us-gaap:FairValueInputsLevel1Member2026-04-030000851520srt:MaximumMember2026-01-032026-04-030000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2026-01-032026-04-030000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-04-0400008515202026-01-032026-04-030000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2026-01-032026-04-030000851520us-gaap:RetainedEarningsMember2025-01-042025-04-040000851520us-gaap:AdditionalPaidInCapitalMember2025-01-030000851520us-gaap:RetainedEarningsMember2026-01-032026-04-0300008515202025-01-042025-04-040000851520us-gaap:FixedIncomeSecuritiesMember2026-04-030000851520us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2026-04-030000851520us-gaap:RestrictedStockUnitsRSUMember2026-01-032026-04-030000851520us-gaap:TreasuryStockCommonMember2025-01-030000851520expo:UnvestedStockOptionsMembersrt:MinimumMember2026-01-032026-04-030000851520us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2026-01-020000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-01-042025-04-040000851520us-gaap:AdditionalPaidInCapitalMember2026-04-030000851520expo:O2026Q2DividendsMemberus-gaap:SubsequentEventMember2026-04-302026-04-300000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-04-040000851520us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2026-04-030000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2025-01-042025-04-040000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2026-01-032026-04-030000851520us-gaap:CashAndCashEquivalentsMember2026-01-020000851520us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2026-01-020000851520us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2026-01-020000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMemberus-gaap:FixedPriceContractMember2025-01-042025-04-040000851520us-gaap:CashEquivalentsMember2026-04-030000851520us-gaap:AdditionalPaidInCapitalMember2025-04-040000851520us-gaap:UnbilledRevenuesMember2026-04-030000851520us-gaap:CommonStockMember2026-01-020000851520us-gaap:TreasuryStockCommonMember2025-01-042025-04-040000851520us-gaap:CommonStockMember2025-01-030000851520expo:VestedRestrictedStockAwardsMember2026-01-032026-04-030000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2026-01-032026-04-030000851520us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2026-04-030000851520us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2026-04-030000851520expo:PhoenixArizonaMember2026-04-030000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2026-01-032026-04-030000851520us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-04-030000851520us-gaap:RestrictedStockUnitsRSUMember2025-01-042025-04-040000851520us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2026-01-020000851520us-gaap:RetainedEarningsMember2025-01-03utr:acreexpo:Segmentxbrli:purexbrli:sharesiso4217:USDxbrli:sharesexpo:Optionexpo:Clientexpo:Stateiso4217:USD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended April 3, 2026

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to___________

Commission File Number 0-18655

EXPONENT, INC.

(Exact name of registrant as specified in its charter)

 

delaware

 

77-0218904

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation or organization)

 

 

 

 

 

149 COMMONWEALTH DRIVE,

MENLO PARK, California

 

94025

(Address of principal executive office)

 

(Zip Code)

 

(650) 326-9400

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

EXPO

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes

 

 

No

 

 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes

 

 

 

No

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

 

Non-accelerated filer

 

Smaller reporting company

 

Emerging growth company

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes

 

 

No

 

 

 

 

As of May 1, 2026, the latest practicable date, the registrant had 48,511,629 shares of common stock outstanding.

 

 


 

EXPONENT, INC.

FORM 10-Q

TABLE OF CONTENTS

 

 

 

 

 

Page

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

3

 

 

 

 

 

Item 1.

 

Financial Statements (unaudited):

 

3

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of April 3, 2026 and January 2, 2026

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Income for the Three Months Ended April 3, 2026 and April 4, 2025

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended April 3, 2026 and April 4, 2025

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended April 3, 2026 and April 4, 2025

 

6

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended April 3, 2026 and April 4, 2025

 

7

 

 

 

 

 

 

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

8

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

19

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

26

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

26

 

 

 

 

 

PART II – OTHER INFORMATION

 

27

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

27

 

 

 

 

 

Item 1A.

 

Risk Factors

 

27

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

27

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

27

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

27

 

 

 

 

 

Item 5.

 

Other Information

 

27

 

 

 

 

 

Item 6.

 

Exhibits

 

28

 

 

 

 

 

 

 

Signatures

 

29

 

 

 


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

EXPONENT, INC.

Condensed Consolidated Balance Sheets

April 3, 2026 and January 2, 2026

(unaudited)

(In thousands, except par value)

 

April 3,
2026

 

 

January 2,
2026

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

118,553

 

 

$

221,930

 

Accounts receivable, net of allowance for contract losses and doubtful accounts
   of $
6,830 and $7,478 at April 3, 2026 and January 2, 2026, respectively

 

 

197,336

 

 

 

181,507

 

Prepaid expenses and other current assets

 

 

24,999

 

 

 

24,143

 

Total current assets

 

 

340,888

 

 

 

427,580

 

 

 

 

 

 

 

 

Property, equipment and leasehold improvements, net of accumulated depreciation and
   amortization of $
124,443 and $122,072 at April 3, 2026 and January 2, 2026,
   respectively

 

 

71,875

 

 

 

71,981

 

Operating lease right-of-use assets

 

 

70,451

 

 

 

73,376

 

Goodwill

 

 

8,607

 

 

 

8,607

 

Deferred income taxes

 

 

63,911

 

 

 

67,075

 

Deferred compensation plan assets

 

 

126,511

 

 

 

123,454

 

Other assets

 

 

5,138

 

 

 

5,446

 

Total assets

 

$

687,381

 

 

$

777,519

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

37,354

 

 

$

30,942

 

Accrued payroll and employee benefits

 

 

82,561

 

 

 

121,302

 

Deferred revenues

 

 

15,568

 

 

 

18,868

 

Operating lease liabilities

 

 

6,715

 

 

 

6,890

 

Total current liabilities

 

 

142,198

 

 

 

178,002

 

 

 

 

 

 

 

 

Other liabilities

 

 

4,311

 

 

 

4,587

 

Deferred compensation plan liabilities

 

 

128,212

 

 

 

128,645

 

Operating lease liabilities

 

 

74,323

 

 

 

75,944

 

Total liabilities

 

 

349,044

 

 

 

387,178

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value; 120,000 shares authorized; 65,707 shares
   issued at April 3, 2026 and January 2, 2026, respectively

 

 

66

 

 

 

66

 

Additional paid-in capital

 

 

386,329

 

 

 

369,747

 

Accumulated other comprehensive loss

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(2,571

)

 

 

(2,290

)

Retained earnings

 

 

682,013

 

 

 

668,423

 

Treasury stock, at cost; 17,092 and 16,087 shares held at April 3, 2026 and January 2, 2026, respectively

 

 

(727,500

)

 

 

(645,605

)

Total stockholders’ equity

 

 

338,337

 

 

 

390,341

 

Total liabilities and stockholders’ equity

 

$

687,381

 

 

$

777,519

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 3 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Income

For the Three Months Ended April 3, 2026 and April 4, 2025

(unaudited)

 

 

 

Three Months Ended

 

(In thousands, except per share data)

 

April 3,
2026

 

 

April 4,
2025

 

Revenues:

 

 

 

 

 

 

Revenues before reimbursements

 

$

151,817

 

 

$

137,437

 

Reimbursements

 

 

14,486

 

 

 

8,070

 

Revenues

 

 

166,303

 

 

 

145,507

 

Operating expenses:

 

 

 

 

 

 

Compensation and related expenses

 

 

91,409

 

 

 

75,903

 

Other operating expenses

 

 

12,825

 

 

 

12,095

 

Reimbursable expenses

 

 

14,486

 

 

 

8,070

 

General and administrative expenses

 

 

6,204

 

 

 

5,007

 

Total operating expenses

 

 

124,924

 

 

 

101,075

 

Operating income

 

 

41,379

 

 

 

44,432

 

Other income, net:

 

 

 

 

 

 

Interest income, net

 

 

1,718

 

 

 

2,714

 

Miscellaneous loss, net

 

 

(758

)

 

 

(9,386

)

Total other income (loss), net

 

 

960

 

 

 

(6,672

)

Income before income taxes

 

 

42,339

 

 

 

37,760

 

Income taxes

 

 

12,770

 

 

 

11,110

 

Net income

 

$

29,569

 

 

$

26,650

 

Net income per share:

 

 

 

 

 

 

Basic

 

$

0.59

 

 

$

0.52

 

Diluted

 

$

0.59

 

 

$

0.52

 

Shares used in per share computations:

 

 

 

 

 

 

Basic

 

 

49,790

 

 

 

51,283

 

Diluted

 

 

50,119

 

 

 

51,650

 

Cash dividends declared per common share

 

$

0.31

 

 

$

0.30

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 4 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Comprehensive Income

For the Three Months Ended April 3, 2026 and April 4, 2025

(unaudited)

 

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Net income

 

$

29,569

 

 

$

26,650

 

Other comprehensive income (loss):

 

 

 

 

 

 

Foreign currency translation
   adjustments, net of tax

 

 

(281

)

 

 

946

 

Comprehensive income

 

$

29,288

 

 

$

27,596

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

 

 

 

- 5 -


 

EXPONENT, INC

Condensed Consolidated Statements of Stockholders’ Equity

For the Three Months Ended April 3, 2026 and April 4, 2025

(unaudited)

 

 

 

Three Months Ended April 3, 2026

 

 

 

Common Stock

 

 

Additional
paid-in

 

 

Accumulated
other
comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

 

 

(In thousands)

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

earnings

 

 

Shares

 

 

Amount

 

 

Total

 

Balance at January 2, 2026

 

 

65,707

 

 

$

66

 

 

$

369,747

 

 

$

(2,290

)

 

$

668,423

 

 

 

16,087

 

 

$

(645,605

)

 

$

390,341

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

249

 

 

 

-

 

 

 

-

 

 

 

(5

)

 

 

58

 

 

 

307

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

5,087

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,087

 

Purchase of treasury shares

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,157

 

 

 

(79,445

)

 

 

(79,445

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(281

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(281

)

Grant of restricted stock units to settle accrued
   bonus

 

 

-

 

 

 

-

 

 

 

13,381

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

13,381

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(2,391

)

 

 

-

 

 

 

-

 

 

 

(129

)

 

 

(2,722

)

 

 

(5,113

)

Exercise of stock options

 

 

-

 

 

 

-

 

 

 

256

 

 

 

 

 

 

 

 

 

(18

)

 

 

214

 

 

 

470

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,979

)

 

 

-

 

 

 

-

 

 

 

(15,979

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

29,569

 

 

 

-

 

 

 

-

 

 

 

29,569

 

Balance at April 3, 2026

 

 

65,707

 

 

$

66

 

 

$

386,329

 

 

$

(2,571

)

 

$

682,013

 

 

 

17,092

 

 

$

(727,500

)

 

$

338,337

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended April 4, 2025

 

 

 

Common Stock

 

 

Additional
paid-in

 

 

Accumulated
other
comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

 

 

(In thousands)

 

Shares

 

 

Amount

 

 

capital

 

 

income (loss)

 

 

earnings

 

 

Shares

 

 

Amount

 

 

Total

 

Balance at January 3, 2025

 

 

65,707

 

 

$

66

 

 

$

345,689

 

 

$

(3,791

)

 

$

624,151

 

 

 

14,893

 

 

$

(545,047

)

 

$

421,068

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

326

 

 

 

-

 

 

 

-

 

 

 

(5

)

 

 

58

 

 

 

384

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

5,028

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,028

 

Purchase of treasury shares

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

65

 

 

 

(5,000

)

 

 

(5,000

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

946

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

946

 

Grant of restricted stock units to settle accrued
   bonus

 

 

-

 

 

 

-

 

 

 

12,179

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

12,179

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(1,499

)

 

 

-

 

 

 

-

 

 

 

(95

)

 

 

(2,667

)

 

 

(4,166

)

Exercise of stock options

 

 

-

 

 

 

-

 

 

 

53

 

 

 

 

 

 

 

 

 

(5

)

 

 

47

 

 

 

100

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,781

)

 

 

-

 

 

 

-

 

 

 

(15,781

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,650

 

 

 

-

 

 

 

-

 

 

 

26,650

 

Balance at April 4, 2025

 

 

65,707

 

 

$

66

 

 

$

361,776

 

 

$

(2,845

)

 

$

635,020

 

 

$

14,853

 

 

$

(552,609

)

 

$

441,408

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 6 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended April 3, 2026 and April 4, 2025

(unaudited)

 

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

29,569

 

 

$

26,650

 

Adjustments to reconcile net income to net cash used in
   operating activities:

 

 

 

 

 

 

Depreciation and amortization of property, equipment and
   leasehold improvements

 

 

2,515

 

 

 

2,492

 

Provision for contract losses and doubtful accounts

 

 

268

 

 

 

256

 

Stock-based compensation

 

 

9,058

 

 

 

8,179

 

Deferred income tax provision

 

 

3,164

 

 

 

(3,226

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(16,097

)

 

 

(5,637

)

Prepaid expenses and other current assets

 

 

(4,755

)

 

 

(3,331

)

Change in operating leases

 

 

1,129

 

 

 

454

 

Accounts payable and accrued liabilities

 

 

6,100

 

 

 

11,595

 

Accrued payroll and employee benefits

 

 

(28,626

)

 

 

(27,571

)

Deferred revenues

 

 

(3,300

)

 

 

(2,587

)

Net cash (used in) provided by operating activities

 

 

(975

)

 

 

7,274

 

Cash flows from investing activities:

 

 

 

 

 

 

Capital expenditures

 

 

(2,453

)

 

 

(1,754

)

Net cash used in investing activities

 

 

(2,453

)

 

 

(1,754

)

Cash flows from financing activities:

 

 

 

 

 

 

Payroll taxes for restricted stock units

 

 

(5,113

)

 

 

(4,166

)

Repurchase of common stock

 

 

(78,761

)

 

 

-

 

Exercise of stock-based payment awards

 

 

777

 

 

 

484

 

Dividends and dividend equivalents rights

 

 

(16,583

)

 

 

(16,367

)

Net cash used in financing activities

 

 

(99,680

)

 

 

(20,049

)

Effect of foreign currency exchange rates on cash and cash equivalents

 

 

(269

)

 

 

741

 

Net decrease in cash and cash equivalents

 

 

(103,377

)

 

 

(13,788

)

Cash and cash equivalents at beginning of period

 

 

221,930

 

 

 

258,901

 

Cash and cash equivalents at end of period

 

$

118,553

 

 

$

245,113

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 7 -


 

EXPONENT, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Basis of Presentation

Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three months ended April 3, 2026 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2026, which was filed with the U.S. Securities and Exchange Commission on February 27, 2026.

The unaudited condensed consolidated financial statements include the accounts of Exponent and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates.

Recent Accounting Pronouncement Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (subtopic 220-40), which requires disclosure of disaggregation of certain relevant expenses included in the statements of operations on an annual and interim basis. ASU 2024-03 will be effective for our annual periods beginning January 2, 2027 and interim periods beginning January 1, 2028. The amendments must be applied retrospectively, and early adoption is permitted. The Company is evaluating the effect that this standard may have on its consolidated financial statements and related disclosures.

Note 2: Revenue Recognition

Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided) then the entity may recognize revenue in the amount to which the entity has a right to invoice.

- 8 -


 

The following table discloses the percent of the Company’s revenue generated from time and materials contracts:

 

 

Three Months Ended

 

 

 

April 3,
2026

 

 

April 4,
2025

 

Engineering & Other Scientific

 

 

62

%

 

 

66

%

Environmental and Health

 

 

15

%

 

 

16

%

Total time and materials revenues

 

 

77

%

 

 

82

%

 

 

 

 

 

 

 

 

For fixed-price contracts, the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides.

The following table discloses the percent of the Company’s revenue generated from fixed price contracts:

 

 

Three Months Ended

 

 

 

April 3,
2026

 

 

April 4,
2025

 

Engineering & Other Scientific

 

 

22

%

 

 

17

%

Environmental and Health

 

 

1

%

 

 

1

%

Total fixed price revenues

 

 

23

%

 

 

18

%

 

 

 

 

 

 

 

 

Deferred revenues represent amounts billed to clients in advance of services provided. During the first quarter of 2026, $7,420,000 of revenues were recognized that were included in the deferred revenue balance at January 2, 2026. During the first quarter of 2025, $5,877,000 of revenues were recognized that were included in the deferred revenue balance at January 3, 2025.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third- party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any service fee associated with reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $6,775,000 and $3,504,000 during the first quarter of 2026 and 2025, respectively.

- 9 -


 

Note 3: Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including money market securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three months ended April 3, 2026 and April 4, 2025. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these financial assets and liabilities was determined using the following inputs at April 3, 2026:

 

 

 

Fair Value Measurements at Reporting Date Using

 

(In thousands)

 

Total

 

 

Quoted
Prices in
Active
Markets
for
Identical
Assets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities (1)

 

$

10,675

 

 

$

10,675

 

 

$

-

 

 

$

-

 

Fixed income trading securities held in deferred
   compensation plan
(2)

 

 

50,738

 

 

 

50,738

 

 

 

-

 

 

 

-

 

Equity trading securities held in deferred
   compensation plan
(2)

 

 

93,470

 

 

$

93,470

 

 

 

-

 

 

 

-

 

Total

 

$

154,883

 

 

$

154,883

 

 

$

-

 

 

$

-

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan (3)

 

 

146,484

 

 

 

146,484

 

 

 

-

 

 

 

-

 

Total

 

$

146,484

 

 

$

146,484

 

 

$

-

 

 

$

-

 

(1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.

(2) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.

(3) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

The fair value of these certain financial assets and liabilities was determined using the following inputs at January 2, 2026:

 

 

Fair Value Measurements at Reporting Date Using

 

(In thousands)

 

Total

 

 

Quoted
Prices in
Active
Markets
for
Identical
Assets
(Level 1)

 

 

Significant
Other
Observable
Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities (1)

 

$

60,170

 

 

$

60,170

 

 

$

-

 

 

$

-

 

Fixed income trading securities held in deferred
   compensation plan
(2)

 

 

45,332

 

 

 

45,332

 

 

 

-

 

 

 

-

 

Equity trading securities held in deferred
   compensation plan
(2)

 

 

94,183

 

 

 

94,183

 

 

 

-

 

 

 

-

 

Total

 

$

199,685

 

 

$

199,685

 

 

$

-

 

 

$

-

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan (3)

 

 

144,706

 

 

 

144,706

 

 

 

-

 

 

 

-

 

Total

 

$

144,706

 

 

$

144,706

 

 

$

-

 

 

$

-

 

 

- 10 -


 

(1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.

(2) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.

(3) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

Money market securities as of April 3, 2026 and January 2, 2026 represent obligations of the United States Treasury. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 6 for additional information about the Company’s deferred compensation plan.

Cash and cash equivalents consisted of the following as of April 3, 2026:

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Classified as current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

107,878

 

 

$

-

 

 

$

-

 

 

$

107,878

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities

 

 

10,675

 

 

 

-

 

 

 

-

 

 

 

10,675

 

Total cash equivalents

 

 

10,675

 

 

 

-

 

 

 

-

 

 

 

10,675

 

Total cash and cash equivalents

 

$

118,553

 

 

$

-

 

 

$

-

 

 

$

118,553

 

 

 

Cash and cash equivalents consisted of the following as of January 2, 2026:

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Classified as current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

161,760

 

 

$

-

 

 

$

-

 

 

$

161,760

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities

 

 

60,170

 

 

 

-

 

 

 

-

 

 

 

60,170

 

Total cash equivalents

 

 

60,170

 

 

 

-

 

 

 

-

 

 

 

60,170

 

Total cash and cash equivalents

 

$

221,930

 

 

$

-

 

 

$

-

 

 

$

221,930

 

 

 

At April 3, 2026 and January 2, 2026, the Company did not have any assets or liabilities valued using significant unobservable inputs.

The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at April 3, 2026 and January 2, 2026, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at April 3, 2026 and January 2, 2026 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheets.

- 11 -


 

Note 4: Net Income Per Share

Basic per share amounts are computed using the weighted-average number of shares of common stock outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of shares of common stock outstanding during the period and, when dilutive, the weighted-average number of potential shares of common stock from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.

The following schedule reconciles the shares used to calculate basic and diluted net income per share:

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Shares used in basic per share computation

 

 

49,790

 

 

 

51,283

 

Effect of dilutive common stock options
   outstanding

 

 

47

 

 

 

103

 

Effect of dilutive restricted stock units
   outstanding

 

 

282

 

 

 

264

 

Shares used in diluted per share
   computation

 

 

50,119

 

 

 

51,650

 

 

Common stock options to purchase 215,833 shares were excluded from the diluted per share calculation for the three months ended April 3, 2026 due to their anti-dilutive effect. Common stock options to purchase 100,833 shares were excluded from the diluted per share calculation for the three months ended April 4, 2025 due to their anti-dilutive effect.

Note 5: Stock-Based Compensation

Restricted Stock Units

Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company’s common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who receives a fully vested restricted stock unit award is also granted a matching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company’s common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will continue to vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.

The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of $3,971,000 and $3,151,000 during the three months ended April 3, 2026 and April 4, 2025, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded

- 12 -


 

stock-based compensation expense associated with the unvested restricted stock unit awards of $4,414,000 and $4,240,000 during the three months ended April 3, 2026 and April 4, 2025, respectively.

Stock Options

Stock options are granted for terms of ten years and generally vest 25% per year over a four-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with stock option grants of $673,000 and $788,000 during the three months ended April 3, 2026 and April 4, 2025, respectively.

The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.

The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights.

The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.

- 13 -


 

Note 6: Deferred Compensation Plans

The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company’s creditors. As of April 3, 2026 and January 2, 2026, the invested amounts under the plans totaled $144,208,000 and $139,515,000, respectively, and are recorded in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. These assets are classified as trading securities and are recorded at fair value with changes recorded as adjustments to miscellaneous loss, net.

As of April 3, 2026 and January 2, 2026, vested amounts due under the plans totaled $146,484,000 and $144,706,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheets. Changes in the liability are recorded as adjustments to compensation expense. During the three months ended April 3, 2026, the Company recognized a reduction to compensation expense of $1,138,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a loss in miscellaneous loss, net. During the three months ended April 4, 2025, the Company recognized a reduction to compensation expense of $9,336,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a loss in miscellaneous loss, net.

Note 7: Supplemental Cash Flow Information

The following is supplemental disclosure of cash flow information:

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Cash paid during period:

 

 

 

 

 

 

Income taxes

 

$

1,204

 

 

$

1,461

 

Non-cash investing and financing activities:

 

 

 

 

 

 

Vested stock unit awards issued to settle accrued bonuses

 

$

13,381

 

 

$

12,179

 

Right-of-use asset obtained in exchange for operating
   lease obligations

 

$

33

 

 

$

-

 

Accrual for capital expenditures

 

$

198

 

 

$

73

 

Repurchases of common stock

 

$

-

 

 

$

5,000

 

 

 

Note 8: Accounts Receivable, Net

At April 3, 2026 and January 2, 2026, accounts receivable, net, was comprised of the following:

 

 

April 3,

 

 

January 2,

 

(In thousands)

 

2026

 

 

2026

 

Billed accounts receivable

 

$

131,134

 

 

$

134,700

 

Unbilled accounts receivable

 

 

73,032

 

 

 

54,285

 

Allowance for contract losses and doubtful accounts

 

 

(6,830

)

 

 

(7,478

)

Total accounts receivable, net

 

$

197,336

 

 

$

181,507

 

 

 

The Company maintains allowances for estimated losses over the remaining contractual life of its receivables resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company’s ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer creditworthiness, current economic conditions, aging of amounts due and future expectations.

- 14 -


 

 

A reconciliation of the beginning and ending amount of the allowance for contract losses and doubtful accounts is as follows:

(In thousands)

 

 

 

Balance at January 2, 2026

 

$

7,478

 

Provision for contract losses and doubtful accounts

 

 

268

 

Write-offs

 

 

(916

)

Balance at April 3, 2026

 

$

6,830

 

 

Note 9: Segment Reporting

The Company has two reportable operating segments based on two primary areas of service. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and Health segment provides services in the areas of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks, and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments, but does not review total assets in evaluating segment performance and capital allocation.

Segment information for the three months ended April 3, 2026 and April 4, 2025 follows:

Revenues

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Engineering and Other Scientific

 

$

141,412

 

 

$

122,135

 

Environmental and Health

 

 

24,891

 

 

 

23,372

 

Total revenues

 

$

166,303

 

 

$

145,507

 

 

Compensation and related expenses

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Engineering and Other Scientific

 

$

64,058

 

 

$

57,248

 

Environmental and Health

 

 

12,897

 

 

 

12,448

 

Total segment compensation and related expenses

 

 

76,955

 

 

 

69,696

 

Corporate compensation and related expenses

 

 

14,454

 

 

 

6,207

 

Total compensation and related expenses

 

$

91,409

 

 

$

75,903

 

 

Operating Income

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Engineering and Other Scientific

 

$

50,415

 

 

$

45,113

 

Environmental and Health

 

 

8,385

 

 

 

8,698

 

Total segment operating income

 

 

58,800

 

 

 

53,811

 

Corporate operating expense

 

 

(17,421

)

 

 

(9,379

)

Total operating income

 

$

41,379

 

 

$

44,432

 

 

 

Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include costs associated with its human resources, finance, information technology, and business

- 15 -


 

development groups; the deferred compensation expense/benefit due to the change in value of assets associated with its deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in its allowance for contract losses and doubtful accounts.

Capital Expenditures

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Engineering and Other Scientific

 

$

632

 

 

$

475

 

Environmental and Health

 

 

39

 

 

 

62

 

Total segment capital expenditures

 

 

671

 

 

 

537

 

Corporate capital expenditures

 

 

1,738

 

 

 

715

 

Total capital expenditures

 

$

2,409

 

 

$

1,252

 

 

 

Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information.

 

 

Depreciation and Amortization

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Engineering and Other Scientific

 

$

1,849

 

 

$

1,826

 

Environmental and Health

 

 

45

 

 

 

47

 

Total segment depreciation and amortization

 

 

1,894

 

 

 

1,873

 

Corporate depreciation and amortization

 

 

621

 

 

 

619

 

Total depreciation and amortization

 

$

2,515

 

 

$

2,492

 

 

No single client comprised more than 10% of the Company’s revenues during the three months ended April 3, 2026 and April 4, 2025.

Note 10: Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of April 3, 2026.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statements of cash flows.

The Company leases office, laboratory, and storage space in 12 states and the District of Columbia, as well as in China, Hong Kong, Switzerland, and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging between one and ten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain.

- 16 -


 

The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the State of Arizona under an agreement that expires in January of 2043 and includes an option to renew for one fifteen-year period.

The Company’s equipment leases are included in the ROU asset and liability balances, but are not material.

The Company leases excess space in its Silicon Valley and Natick facilities. Rental income of $333,000 and $191,000 was included in other income for the three months ended April 3, 2026 and April 4, 2025, respectively.

The components of lease expense included in other operating expenses on the condensed consolidated statements of income were as follows:

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Operating lease cost

 

$

3,196

 

 

$

3,212

 

Variable lease cost

 

 

630

 

 

 

303

 

Short-term lease cost

 

 

266

 

 

 

356

 

 

 

Supplemental cash flow information related to operating leases was as follows:

 

 

Three Months Ended

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Cash paid for amounts included in the measurement of operating
   lease liabilities

 

$

3,109

 

 

$

2,602

 

 

 

Supplemental balance sheet information related to operating leases was as follows:

 

April 3,
2026

 

 

April 4, 2025

 

Weighted Average Remaining Lease Term

13.0 years

 

 

13.6 years

 

Weighted Average Discount Rate

6.3%

 

 

6.3%

 

 

 

Maturities of operating lease liabilities as of April 3, 2026:

(In thousands)

 

Operating Leases

 

2026 (excluding the three months ended April 3, 2026)

 

$

6,180

 

2027

 

 

8,194

 

2028

 

 

10,914

 

2029

 

 

9,600

 

2030

 

 

9,092

 

Thereafter

 

 

80,286

 

Total lease payments

 

$

124,266

 

Less imputed interest

 

 

43,228

 

Total lease liability

 

$

81,038

 

 

 

Note 11: Contingencies

The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.

- 17 -


 

Note 12: Subsequent Events

On April 30, 2026, the Company announced that its Board of Directors approved a cash dividend of $0.31 per share of the Company’s common stock, payable June 18, 2026, to stockholders of record as of June 5, 2026. On April 30, 2026, the Company announced that its Board of Directors authorized $50 million for the repurchase of the Company's common stock which is in addition to the amounts remaining under prior repurchase authorizations. These repurchase authorizations have no expiration date.

- 18 -


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements and notes thereto for the fiscal year ended January 2, 2026, which are contained in our fiscal 2025 Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission on February 27, 2026 (our “2025 Annual Report”).

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to us or our management, identify such forward-looking statements. Such statements reflect the current views of us or our management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our 2025 Annual Report under the heading “Risk Factors” and elsewhere in this report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations we contemplated will be achieved. Due to such uncertainties and risks, you are warned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not intend to release publicly any updates or revisions to any such forward-looking statements.

Business Overview

Exponent, Inc. is an engineering and scientific consulting firm providing solutions to complex problems. Our interdisciplinary organization of scientists, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 55 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

CRITICAL ACCOUNTING ESTIMATES

There have been no significant changes in our critical accounting estimates during the three months ended April 3, 2026, as compared to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2025 Annual Report.

RESULTS OF CONSOLIDATED OPERATIONS

Executive Summary

Revenues for the first quarter of 2026 increased 14% to $166,303,000 as compared to $145,507,000 during the same period last year. Revenues before reimbursements for the first quarter of 2026 increased 10% to $151,817,000 as compared to $137,437,000 during the same period last year. Revenue growth was driven by proactive engagements, including user research studies for consumer electronics clients integrating artificial intelligence into their devices, as well as risk management work for utility clients evaluating asset performance under extreme weather conditions. Reactive engagements also contributed to our growth, with increased dispute-related and failure analysis demand across construction projects, energy facilities, and medical devices.

- 19 -


 

Net income increased 11% to $29,569,000 during the first quarter of 2026 as compared to $26,650,000 during the same period last year. Diluted earnings per share increased to $0.59 per share during the first quarter of 2026 as compared to $0.52 during the same period last year. During the first quarter of 2026, we realized a negative tax impact associated with stock-based awards of $896,000 as compared to a negative tax impact of $469,000 during the same period last year. The change in the tax impact associated with stock-based awards was due to the change in the difference of the value of our common stock between the grant date and the release date for the restricted stock units released during the first quarter of 2026 as compared to the first quarter of 2025.

We remain focused on building our world-class engineering and scientific team to position us at the forefront of innovation and meet the ever-changing needs of our clients and the market. We also remain focused on capitalizing on emerging growth areas, managing other operating expenses, generating cash from operations, maintaining a strong balance sheet and undertaking activities such as share repurchases and dividends to enhance stockholder value.

Overview of the Three Months Ended April 3, 2026

During the first quarter of 2026, billable hours increased 6% to 399,000 as compared to 376,000 during the same period last year. Our utilization increased 1% to 76% as compared to 75% during the same period last year. Technical full-time equivalent employees increased 5% to 1,013 during the first quarter of 2026 as compared to 966 during the same period last year.

Three Months Ended April 3, 2026 compared to Three Months Ended April 4, 2025

Revenues

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Engineering and Other Scientific

 

$

141,412

 

 

$

122,135

 

 

 

15.8

%

Percentage of total revenues

 

 

85.0

%

 

 

83.9

%

 

 

 

Environmental and Health

 

 

24,891

 

 

 

23,372

 

 

 

6.5

%

Percentage of total revenues

 

 

15.0

%

 

 

16.1

%

 

 

 

Total revenues

 

$

166,303

 

 

$

145,507

 

 

 

14.3

%

 

The increase in revenues for our Engineering and Other Scientific segment was due to an increase in billable hours and an increase in billing rates. Growth during the quarter was primarily driven by user research studies in consumer electronics and risk management in the utilities sector, along with reactive engagements in the energy and life sciences sectors. During the first quarter of 2026, billable hours for this segment increased by 9% to 327,000 as compared to 300,000 during the same period last year. Utilization for this segment increased to 77% during the first quarter of 2026 as compared to 76% during the same period last year. Technical full-time equivalent employees in this segment increased 7% to 814 during the first quarter of 2026 as compared to 762 for the same period last year.

 

The increase in revenues for our Environmental and Health segment was due to an increase in billing rates partially offset by a decrease in billable hours. Growth in this segment was primarily driven by regulatory consulting in the chemical industry. During the first quarter of 2026, billable hours for this segment decreased by 5% to 72,000 as compared to 76,000 during the same period last year. Utilization in this segment decreased to 69% during the first quarter of 2026 as compared to 72% during the same period last year. Technical full-time equivalent employees in this segment decreased 2% to 199 during the first quarter of 2026 as compared to 204 during the same period last year.

Compensation and Related Expenses

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Compensation and related expenses

 

$

91,409

 

 

$

75,903

 

 

 

20.4

%

Percentage of total revenues

 

 

55.0

%

 

 

52.2

%

 

 

 

 

 

- 20 -


 

The increase in compensation and related expenses during the first quarter of 2026 was due to an increase in payroll, an increase in bonuses and the change in the value of assets associated with our deferred compensation plan. During the first quarter of 2026, payroll expense increased by $4,158,00 due to an increase in technical full-time equivalent employees and the impact of annual salary increases. During the first quarter of 2026, bonus expense increased by $2,938,000 due to a corresponding increase in our bonus pool which is 33% of income before income taxes, interest income, bonus expense, and stock-based compensation. During the first quarter of 2026, deferred compensation expense increased by $8,198,000 with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. During the first quarter of 2026, the value of plan assets decreased by $1,138,000 as compared to a decrease of $9,336,000 during the same period last year.

 

Other Operating Expenses

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Other operating expenses

 

$

12,825

 

 

$

12,095

 

 

 

6.0

%

Percentage of total revenues

 

 

7.7

%

 

 

8.3

%

 

 

 

 

 

Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating expenses during the first quarter of 2026 was primarily due to an increase in occupancy expense of $388,000 and an increase in computer-related expenses of $255,000. The increase in occupancy expense was due to an increase in facility repairs and maintenance. The increase in computer-related expenses was due to continued investments in our corporate infrastructure. We expect other operating expenses to grow as we selectively add new talent and make investments in our corporate infrastructure.

Reimbursable Expenses

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Reimbursable expenses

 

$

14,486

 

 

$

8,070

 

 

 

79.5

%

Percentage of total revenues

 

 

8.7

%

 

 

5.5

%

 

 

 

 

 

The amount of reimbursable expenses will vary from quarter to quarter depending on the nature of our projects. The increase in reimbursable expenses was due to an increase in reimbursable expenses associated with user research projects.

General and Administrative Expenses

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

General and administrative expenses

 

$

6,204

 

 

$

5,007

 

 

 

23.9

%

Percentage of total revenues

 

 

3.7

%

 

 

3.4

%

 

 

 

 

 

The increase in general and administrative expenses was primarily due to an increase in travel and meals of $548,000 and several other individually insignificant increases. The increase in travel and meals was due to an increase in client and business development activities and an increase in recruiting-related activities associated with the increase in technical full-time equivalent employees. We expect general and administrative expenses to increase as we selectively add new talent and expand our business development and staff development initiatives.

- 21 -


 

Operating Income

 

 

Three Months Ended

 

 

 

 

(In thousands)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Engineering and Other Scientific

 

$

50,415

 

 

$

45,113

 

 

 

11.8

%

Environmental and Health

 

 

8,385

 

 

 

8,698

 

 

 

-3.6

%

Total segment operating income

 

 

58,800

 

 

 

53,811

 

 

 

9.3

%

Corporate operating expense

 

 

(17,421

)

 

 

(9,379

)

 

 

85.7

%

Total operating income

 

$

41,379

 

 

$

44,432

 

 

 

-6.9

%

The increase in operating income for our Engineering and Other Scientific segment during the first quarter of 2026 as compared to the same period last year was due to an increase in net revenues and an increase in utilization. The decrease in operating income for our Environmental and Health segment during the first quarter of 2026 was due to a decrease in utilization.

Certain operating expenses are excluded from our measure of segment operating income. These expenses include the costs associated with our human resources, finance, information technology, corporate, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with our deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in our allowance for contract losses and doubtful accounts.

The increase in corporate operating expenses was due to the change in value of assets associated with our deferred compensation plan. During the first quarter of 2026, deferred compensation expense increased by $8,198,000 with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. During the first quarter of 2026, the value of plan assets decreased by $1,138,000 as compared to a decrease of $9,336,000 during the same period last year.

 

Other Income, Net

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Other income / (loss), net

 

$

960

 

 

$

(6,672

)

 

 

-114.4

%

Percentage of total revenues

 

 

0.6

%

 

 

-4.6

%

 

 

 

 

Other income, net, consists primarily of changes in the value of assets associated with our deferred compensation plan, interest income earned on available cash, cash equivalents and short-term investments, and rental income from leasing space in our Silicon Valley and Natick facilities. The increase in other income, net, was primarily due to the change in value of assets associated with our deferred compensation plan partially offset by a decrease in interest income. During the first quarter of 2026, other income, net, increased by $8,198,000 with a corresponding increase to deferred compensation expense as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. During the first quarter of 2026, the value of plan assets decreased by $1,138,000 as compared to a decrease of $9,336,000 during the same period last year. During the first quarter of 2026 interest income decreased by $996,000 due to a decrease in interest rates and lower average cash equivalent balances.

 

Income Taxes

 

 

Three Months Ended

 

 

 

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

 

Percent
Change

 

Income taxes

 

$

12,770

 

 

$

11,110

 

 

 

14.9

%

Percentage of total revenues

 

 

7.7

%

 

 

7.6

%

 

 

 

Effective tax rate

 

 

30.2

%

 

 

29.4

%

 

 

 

 

- 22 -


 

 

 

During the first quarter of 2026, we realized a negative tax impact associated with stock-based awards of $896,000 as compared to a negative tax impact of $469,000 during the same period last year. The change in the tax impact associated with stock-based awards was due to the change in the difference of the value of our common stock between the grant date and the release date for the restricted stock units released during the first quarter of 2026 as compared to the first quarter of 2025. Excluding the negative tax impact, our consolidated tax rate was 28.0% in the first quarter of 2026, as compared to 28.2% for the same period in 2025.

 

LIQUIDITY AND CAPITAL RESOURCES

 

We believe our existing balances of cash, cash equivalents, short-term investments and cash generated from operations will be sufficient to satisfy our working capital needs, capital expenditures, outstanding commitments, stock repurchases, dividends and other liquidity requirements over at least the next 12 months.

 

 

Three Months Ended

 

(in thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Net cash (used in) provided by operating activities

 

$

(975

)

 

$

7,274

 

Net cash used in investing activities

 

 

(2,453

)

 

 

(1,754

)

Net cash used in financing activities

 

 

(99,680

)

 

 

(20,049

)

 

We financed our business during the first three months of 2026 through available cash. As of April 3, 2026, our cash and cash equivalents were $118,553,000 as compared to $221,930,000 at January 2, 2026.

Generally, our net cash provided by operating activities is used to fund our day to day operating activities. First quarter operating cash requirements are generally higher due to payment in the first quarter of our annual bonuses accrued during the prior year. Our largest source of operating cash flows is collections from our clients. Our primary uses of cash from operating activities are for employee related expenditures, leased facilities, taxes, and general operating expenses.

The increase in net cash used in investing activities during the first three months of 2026, as compared to the same period last year, was due to an increase in capital expenditures. The increase in capital expenditures was due to an increase in investment in our corporate infrastructure.

The increase in net cash used in financing activities during the first three months of 2026, as compared to the same period last year, was primarily due to an increase in repurchases of our common stock.

We lease office, laboratory, and storage space in 12 states and the District of Columbia, as well as in China, Hong Kong, Switzerland, and the United Kingdom under non-cancellable operating lease arrangements that expire at various dates through 2033. On June 19, 2024, we entered into an agreement with the State of Arizona to extend our land lease for 15 years beginning on January 17, 2028. We are currently obligated to make payments under the lease of $1,009,000 per year, which obligation will continue at that level until January 16, 2028. Beginning on January 17, 2028, our payments under the lease will increase to approximately $6,183,000 per year for the 15-year extension term with adjustments to the annual rent payment in 2033 and 2038 based on the consumer price index.

We expect to continue our investing activities, including capital expenditures. Furthermore, cash reserves may be used to repurchase common stock under our stock repurchase programs, pay dividends, procure facilities and equipment or strategically acquire professional service firms that are complementary to our business.

- 23 -


 

We maintain nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Vested amounts due under the plans of $128,212,000 were recorded as a long-term liability on our unaudited condensed consolidated balance sheet at April 3, 2026. Vested amounts due under the plans of $18,272,000 were recorded as a current liability on our unaudited condensed consolidated balance sheet at April 3, 2026. Company assets that are designated to fund the benefits under the plans are held in a rabbi trust and are subject to the claims of our creditors. As of April 3, 2026, invested amounts under the plans of $126,511,000 were recorded as a non-current asset on our unaudited condensed consolidated balance sheet. As of April 3, 2026, invested amounts under the plans of $17,697,000 were recorded as other current assets on our unaudited condensed consolidated balance sheet.

As permitted under Delaware law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or director is, or was serving, at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the officer’s or director’s lifetime. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We believe the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

Non-GAAP Financial Measures

Regulation G, Conditions for Use of Non-Generally Accepted Accounting Principles ("Non-GAAP") Financial Measures, and other U.S. Securities and Exchange Commission (“SEC”) rules and regulations define and prescribe the conditions for use of Non-GAAP financial information. Generally, a Non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. We closely monitor two financial measures, EBITDA and EBITDAS, which meet the definition of Non-GAAP financial measures. We define EBITDA as net income before income taxes, net interest income, depreciation and amortization. We define EBITDAS as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. These measures are used to evaluate our financial results, develop budgets and determine employee compensation. These measures, however, should be considered in addition to, and not as a substitute for or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the Non-GAAP measures to the nearest comparable GAAP measure is set forth below.

The following table is a reconciliation of EBITDA and EBITDAS to the most comparable GAAP measure, net income, for the three months ended April 3, 2026 and April 4, 2025:

 

 

Three Months Ended

 

(in thousands)

 

April 3,
2026

 

 

April 4,
2025

 

Net income

 

$

29,569

 

 

$

26,650

 

Add back (subtract):

 

 

 

 

 

 

Income taxes

 

 

12,770

 

 

 

11,110

 

Interest income, net

 

 

(1,718

)

 

 

(2,714

)

Depreciation and amortization

 

 

2,515

 

 

 

2,492

 

EBITDA

 

 

43,136

 

 

 

37,538

 

Stock-based compensation

 

 

9,058

 

 

 

8,179

 

EBITDAS

 

$

52,194

 

 

$

45,717

 

 

- 24 -


 

 

The following table shows EBITDA (determined as shown in the reconciliation table above) as a percentage of revenues before reimbursements for the three months ended April 3, 2026 and April 4, 2025:

 

 

Three Months Ended

 

(in thousands, except percentages)

 

April 3,
2026

 

 

April 4,
2025

 

Revenues before reimbursements

 

$

151,817

 

 

$

137,437

 

EBITDA

 

$

43,136

 

 

$

37,538

 

EBITDA as a % of revenues before
   reimbursements

 

 

28.4

%

 

 

27.3

%

 

The increase in EBITDA as a percentage of revenues before reimbursements, during the first quarter of 2026 as compared to the same period last year, was primarily due to an increase in net revenues and an increase in utilization.

 

 

 

- 25 -


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to interest rate risk associated with our balances of cash and cash equivalents. We manage our interest rate risk by maintaining an investment portfolio primarily consisting of debt instruments with high credit quality and relatively short average effective maturities in accordance with our investment policy. The maximum effective maturity of any issue in our portfolio is three years and the maximum average effective maturity of the portfolio cannot exceed 12 months. If interest rates were to instantaneously increase or decrease by 100 basis points, the change in the fair market value of our portfolio of cash equivalents would not have a material impact on our financial statements. We do not use derivative financial instruments in our portfolio. There have not been any material changes during the period covered by this Quarterly Report on Form 10-Q to our interest rate risk exposures, or how these exposures are managed. Notwithstanding our efforts to manage interest rate risk, there can be no assurances that we will be adequately protected against the risks associated with interest rate fluctuations.

We have foreign currency risk related to our revenues and expenses denominated in currencies other than the U.S. dollar, primarily the British Pound, the Euro, the Chinese Yuan, the Hong Kong Dollar, and the Singapore Dollar. Accordingly, changes in exchange rates may negatively affect the revenues and net income of our foreign subsidiaries as expressed in U.S. dollars.

At April 3, 2026, we had net assets of approximately $16.4 million with a functional currency of the British Pound, net assets of approximately $3.8 million with a functional currency of the Hong Kong Dollar, net assets of approximately $2.5 million with a functional currency of the Chinese Yuan, and net assets of approximately $1.8 million with a functional currency of the Singapore Dollar associated with our operations in the United Kingdom, Hong Kong, China and Singapore, respectively.

We also have foreign currency risk related to foreign currency transactions and monetary assets and liabilities denominated in currencies that are not the functional currency. We have experienced and will continue to experience fluctuations in our net income as a result of gains (losses) on these foreign currency transactions and the remeasurement of monetary assets and liabilities. At April 3, 2026, we had net assets denominated in the non-functional currency of approximately $5.9 million.

We do not use foreign exchange contracts to hedge any foreign currency exposures. To date, the impacts of foreign currency exchange rate changes on our consolidated revenues and consolidated net income have not been significant. However, our continued international growth increases our exposure to exchange rate fluctuations and as a result such fluctuations could have a significant impact on our future results of operations.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, an evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this quarterly report. Based on that evaluation, the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, concluded that, as of April 3, 2026, the Company’s disclosure controls and procedures were effective.

We review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis, to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three-month period ended April 3, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

- 26 -


 

PART II - OTHER INFORMATION

The Company is not engaged in any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes from risk factors as previously discussed under the heading “Risk Factors” in the Company’s 2025 Annual Report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information on the Company’s repurchases of the Company’s common stock for the three months ended April 3, 2026:

 

(In thousands, except price per share)

 

Total
Number
of Shares
Purchased

 

 

Average
Price
Paid Per
Share

 

 

Total
Number of
Shares
Purchased
as Part of
Publicly
Announced
Programs

 

 

Approximate
Dollar Value
of Shares That
May Yet Be
Purchased
Under the
Programs (
1)

 

January 3 to January 30

 

 

-

 

 

$

-

 

 

 

-

 

 

$

96,483

 

January 31 to February 27

 

 

611

 

 

 

69.10

 

 

 

611

 

 

 

54,229

 

February 28 to April 3

 

 

545

 

 

 

66.95

 

 

 

545

 

 

 

17,721

 

Total

 

 

1,156

 

 

$

68.09

 

 

 

1,156

 

 

$

17,721

 

 

 

(1)
Repurchases of the Company’s common stock were made pursuant to a repurchase program authorized by the Company’s Board of Directors. On October 30, 2025, the Company's Board of Directors announced approval of $100,000,000 for the repurchase of the Company's common stock. The Company's repurchase authorization has no expiration date.

 

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Plans. None of the Company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s fiscal quarter ended April 3, 2026.

 

- 27 -


 

Item 6. Exhibits

(a)
Exhibit Index

 

  31.1

Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) under the Securities Exchange Act of 1934.

 

 

  31.2

Certification of Chief Financial Officer pursuant to Rule 13a – 14(a) under the Securities Exchange Act of 1934.

 

 

  32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

 

 

  32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

 

 

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Document

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

Exhibit 104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

- 28 -


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

EXPONENT, INC.

 

 

(Registrant)

 

 

 

Date: May 8, 2026

 

 

 

 

/s/ Catherine Ford Corrigan

 

 

Catherine Ford Corrigan, Ph.D., Chief Executive Officer

 

 

 

 

 

 

 

 

/s/ Eric Anderson

 

 

Eric Anderson, Chief Financial Officer

 

- 29 -


FAQ

How did Exponent (EXPO) perform financially in Q1 2026?

Exponent delivered higher results in Q1 2026, with revenue of $166.3 million, up from $145.5 million, and net income of $29.6 million versus $26.7 million a year earlier. Diluted EPS rose to $0.59 from $0.52.

What drove revenue growth for Exponent (EXPO) in the first quarter of 2026?

Revenue growth came mainly from the Engineering and Other Scientific segment, where revenue increased to $141.4 million. Key drivers included user research for consumer electronics integrating artificial intelligence and risk management work for utilities, plus higher dispute and failure analysis activity.

How profitable was Exponent (EXPO) on an EBITDA basis in Q1 2026?

Exponent generated EBITDA of $43.1 million in Q1 2026, up from $37.5 million a year earlier. EBITDA represented 28.4% of revenues before reimbursements of $151.8 million, compared with 27.3% on $137.4 million in the prior-year quarter.

What capital return actions did Exponent (EXPO) take and authorize in early 2026?

In Q1 2026, Exponent paid a $0.31 per-share dividend and repurchased 1.156 million shares for about $78.8 million. On April 30, 2026, the board also authorized an additional $50 million for share repurchases with no expiration date.

What is Exponent (EXPO)’s cash position and operating cash flow trend in Q1 2026?

Exponent ended Q1 2026 with cash and cash equivalents of $118.6 million, down from $221.9 million at year-end 2025. Operating activities used $1.0 million of cash, compared with providing $7.3 million in the prior-year quarter, reflecting bonus payments and capital returns.

How did Exponent’s (EXPO) business segments perform in Q1 2026?

The Engineering and Other Scientific segment grew revenue to $141.4 million and operating income to $50.4 million. The Environmental and Health segment reported revenue of $24.9 million and operating income of $8.4 million, with lower billable hours but higher billing rates.

What dividend did Exponent (EXPO) declare after Q1 2026?

On April 30, 2026, Exponent’s board approved a cash dividend of $0.31 per share, payable on June 18, 2026 to stockholders of record as of June 5, 2026, continuing the company’s pattern of regular cash dividends.